MMJ gets serious in Australia
Published 23-OCT-2015 11:34 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MMJ PhytoTech (ASX:MMJ) is getting serious about the Australian market, appointing a legal advisor and raising cash as regulatory hurdles in front of a medicinal cannabis industry start to evaporate.
It comes after the Turnbull government announced that it would allow the states to legalise the growth of cannabis for medical purposes, opening the door for a medical cannabis industry to get started.
States including Victoria and News South Wales have already taken key steps in making this a reality, but the commitment to introduce national legislation on the issue is a boon for companies which could potentially play in the space.
MMJ PhytoTech, since the federal move was announced on Friday, has rocketed up by more than 20% to be at 37.5c at the time of writing.
MMJ had previously signalled its intent to investigate the Australian market on the back of positive noises from the Victorian government, but the federal government cooing to the party has triggered firmer action.
It has appointed national legal firm Piper Alderman to act as a regulatory advisor, and raised $2 million via a placement in Europe to fund the move into Australia.
MMJ PhytoTech, which is an ASX-listed company, has has to head to other jurisdictions such as Canada and Israel in order to build a fully-integrated medical cannabis company.
It has a ‘farm to pharma’ strategy, which includes the growing of cannabis; the extraction of key compounds and manufacture of medical products from those compounds; and a research & development capacity.
Managing director Andreas Gedeon said the positive shift in the Australian regulatory environment would provide a unique opportunity for MMJ.
“We’re incredibly supportive of the recent announcement from the federal government and it is this which has driven our decision to expedite our strategy to enter the Australian market,” he said.
“Our background within the medical cannabis sector provides us with the necessary experience and expertise to quickly establish ourselves as a leading player in the domestic space.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
